Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term outcomes and treatment response in early-stage invasive lobular carcinoma: insights from a nationwide population-based study.

ESMO open·2026
Same author

Retrospective study evaluating dental side effects of radiotherapy in patients treated for head and neck cancer.

Journal of stomatology, oral and maxillofacial surgery·2024
Same author

Risk factors for imminent fractures: a substudy of the FRISBEE cohort.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2021
Same author

Discriminating value of HR-pQCT for fractures in women with similar FRAX scores: A substudy of the FRISBEE cohort.

Bone·2020
Same author

Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

What is the validity of self-reported fractures?

Bone reports·2020

Related Experiment Videos

[Stage IV NSCLC. Prognostic factors].

M Paesmans1

  • 1Data Centre--Institut Jules-Bordet, 1 Rue Héger-Bordet, Brussels, Belgium. marianne.paesmans@bordet.be

Revue Des Maladies Respiratoires
|November 26, 2008
PubMed
Summary

Identifying reliable prognostic factors is crucial for stage IV lung cancer treatment and research. Key indicators include good performance status, female sex, single metastasis, and specific biological markers like normal white blood cell count and low Cyfra 21-1.

Area of Science:

  • Oncology
  • Clinical Research
  • Biostatistics

Context:

  • Prognostic factors are vital for therapeutic decisions and population-level interpretation of lung cancer data.
  • Few prognostic factors for lung cancer, especially stage IV, possess independent and reproducible value.
  • Existing literature highlights host-related factors (performance index, sex) and tumor-related factors (metastatic site, absence of cutaneous metastasis) as favorable.

Purpose:

  • To identify and validate independent and reproducible prognostic factors for stage IV lung cancer.
  • To assess the prognostic impact of biological variables, including leucocytosis, anemia, calcemia, Cyfra 21-1, and lactate dehydrogenase (LDH).
  • To explore the potential of novel factors like standardized uptake value (SUV) from PET-scans and to develop validated prognostic classifications.

Related Experiment Videos

Summary:

  • Host-related factors like good performance index and female sex are favorable prognostic indicators.
  • Tumor-related factors such as a single metastatic site and absence of cutaneous metastasis show prognostic value.
  • Biological markers including normal leucocytosis, absence of anemia, normal calcemia, low Cyfra 21-1, and low serum LDH are associated with a favorable prognosis.

Impact:

  • Enhances clinical decision-making for stage IV lung cancer patients.
  • Informs the design of future clinical trials and research endeavors.
  • Contributes to the development of more accurate prognostic models and classifications for lung cancer.